3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow HBV: new trials by email Literature Review of HBV trials Research Report on HBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen IMIQUIMOD cream, HEPATITIS B SURFACE ANTIGEN - Cirrhosis, Liver, Vaccination Failure | Phase 2 | Unknown | Central Hospital, Nancy, France | 60 | 2021-11-01 | 2021-08-31 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 122 | 2020-06-03 | 2021-08-26 |
| Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE - PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 40 | 2012-05-01 | 2012-04-25 |
Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Digestive System Neoplasms (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Digestive System Diseases (3) · Liver Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood-Borne Infections (1) · Chronic Disease (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Disease Attributes (1) · Fibrosis (1) · Hepadnaviridae Infections (1) · Hepatitis (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Infections (1)
APG-1387 (1) · Hepatitis B Surface Antigens (1) · Sorafenib (1) · entecavir (1)
Ascentage Pharma Group Inc. (1) · Central Hospital, Nancy, France (1) · Shandong Cancer Hospital and Institute (1)
China (2)
Jinlong Song, MD (1) · Yifan Zhai, MD, PhD (1)